Literature DB >> 4288226

Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine.

R E Weibel, J Stokes, M B Leagus, C C Mascoli, M R Hilleman.   

Abstract

Mesh：

Substances：

Year:  1966        PMID： 4288226     DOI： 10.1164/arrd.1966.94.3.362

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN： 0003-0805


× No keyword cloud information.
  8 in total

Review 1.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

2.  Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

Authors:  R A Tripp; D Moore; L Jones; W Sullender; J Winter; L J Anderson
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.

Authors:  M Oumouna; J W Mapletoft; B C Karvonen; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

5.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

Review 6.  Priorities for developing respiratory syncytial virus vaccines in different target populations.

Authors:  Simon B Drysdale; Rachael S Barr; Christine S Rollier; Christopher A Green; Andrew J Pollard; Charles J Sande
Journal:  Sci Transl Med       Date:  2020-03-18       Impact factor: 19.319

7.  Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Authors:  Patricia A Jorquera; Youngjoo Choi; Katie E Oakley; Thomas J Powell; James G Boyd; Naveen Palath; Lia M Haynes; Larry J Anderson; Ralph A Tripp
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

8.  The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection.

Authors:  Abhijeet A Bakre; Jennifer L Harcourt; Lia M Haynes; Larry J Anderson; Ralph A Tripp
Journal:  Vaccines (Basel)       Date:  2017-07-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.